Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.
  • ArrayPharmacy
  • call for care 214.379.2700

    Choice Cancer Care is here for you 9AM – 5PM Monday – Friday

    Inquiring after hours? Complete our contact form and we will be in touch as soon as possible.


  • Patientportal

    Access Your Portal To Health at Choice Cancer Care.

    Learn more about becoming a CCC Patient, including insurance information and patient rights, or login to access your personal portal for in-depth information about your health.

    LoginSign UpLearn More

  • Patientforms
  • get a second opinion

    Recent Diagnosis? Gain Confidence With A Second Opinion.

    Find out what to ask your doctor, what a second opinion could mean for you, and take the steps to get you on the right path to treat your cancer.

    Contact Us Online to Schedule an Appointment:

    • certified

      Choice Cancer Care is proud to be recognized by the Quality Oncology Practice Initiative (QOPI®) for excellence in quality, and safety in the administration of cancer care.

      Learn More

    Increasing Survival Rates for ‘Incurable’ Cancer

    High-dose Radiation May be the Answer

    Research presented at the 2018 Annual Meeting of the American Society for Radiation Oncology (ASTRO) suggests that high-dose radiation therapy improves survival for oligometastatic patients. When patients have cancer that spreads to the rest of their body like their bones or brain, in the past they would have been considered incurable.

    “There’s a theory—called the oligometastatic theory—that if a patient only has a few spots of cancer returning, those spots could be killed with radiation or surgery to improve their survival.” In a prepared statement, lead author of the research, David Palma (MD, Ph.D.) stated, “Now, we’ve been able to show, for the first time in a randomized trial, that high-dose radiation can effectively treat these limited recurrences, and we’ve been able to increase survival by a median of 13 months.”

    Palma et al. enrolled 99 patients from Scotland, the Netherlands, Australia, and Canada in what researchers have called the first randomized clinical trial of its kind. Participants all had recurring cancer after receiving previous treatment. All had life expectancies over six months.

    The trial spanned four years, from 2012 to 2016. Participants were assigned randomly into two treatment groups: palliative standard of care (SOC) treatments and SOC treatments plus stereotactic body radiation therapy (SBRT)—in a 1:2 ratio.

    According to Palma’s statement, the group with SBRT treatments lived “considerably longer” than the group who received SOC treatments alone. The median survival was 41 months overall for the SBRT group while the SOC-only group’s overall survival was 28 months. Additionally, the participants in the SBRT group doubled how they lived without any cancer growth.

    SBRT is associated with “severe side effects,” including death. Palma, however, explains, “for patients whose cancers have spread, and who are not expected to survive otherwise,” the benefit outweighs the risks. 

    Cancer Screening Guidelines

    Screening can help doctors discover and treat some types of cancer early. Usually, cancer treatment is more effective when the disease is detected in its early stages and there could be a better chance of curing the cancer. Some...

    Learn More

    Learn About Your Options

    Your journey with cancer is influenced by several factors. These factors include your overall condition, the specific characteristics of your cancer, and whether the goal of treatment is to eradicate your cancer, stop your cancer from spreading to other areas...

    Learn More